ライフサイエンスコーパス: cell therapy

1 rticularly chimeric antigen receptor (CAR) T-cell therapy.

2 d stem cell production in vitro and clinical cell therapy.

3 mising strategy to improve vaccination and T cell therapy.

4 patients in remission after anti-CD19 CAR T-cell therapy.

5 tically modified T cells, most notably CAR T-cell therapy.

6 include small molecules, gene delivery, and cell therapy.

7 associated with chimeric antigen receptor T-cell therapy.

8 ancies and revitalized the field of adoptive cell therapy.

9 nventional chimeric antigen receptor (CAR) T-cell therapy.

10 icit therapeutic responses in the adoptive T-cell therapy.

11 ells for safer and more efficacious adoptive cell therapy.

12 with immunotherapy, particularly adoptive T cell therapy.

13 ritical determinant of successful adoptive T cell therapy.

14 se syndrome with chimeric antigen receptor T cell therapy.

15 f new vaccination strategies with adoptive T cell therapy.

16 cision medicine, tissue engineering and stem cell therapy.

17 sess safety and feasibility of Hu19-CD828Z T-cell therapy.

18 ence of chimeric antigen receptor macrophage cell therapy.

19 ng as the most promising means of allogeneic cell therapy.

20 ed, combining GSI with concurrent BCMA CAR T-cell therapy.

21 eno-free platform for biomedical research or cell therapy.

22 the blood-brain barrier, to monitor gene and cell therapy.

23 y limit efficacy of BCMA-directed adoptive T-cell therapy.

24 r basic science, biotechnology, and gene and cell therapy.

25 presenting a safe and potent anti-CD19 CAR T cell therapy.

26 fety and efficacy outcomes of corneal stroma cell therapy.

27 o toxicity or tumorigenicity of the HSC-iNKT cell therapy.

28 angiogenesis compared with diabetic control cell therapy.

29 lopment of CRS and neurotoxicity after CAR-T cell therapy.

30 CD8+ T cells in a mouse model of adoptive T cell therapy.

31 s and clinical scale production of cells for cell therapy.

32 ines on the care of children receiving CAR T cell therapy.

33 proaches such as chimeric antigen receptor T cell therapy.

34 xcess IL-18, and chimeric antigen receptor T-cell therapy.

35 phic HLAs form the primary immune barrier to cell therapy.

36 ng of direct remuscularization approaches to cell therapy.

37 engineering, antibody humanization and CAR-T cell therapy.

38 mit the potential lifelong benefits of CAR T cell therapy.

39 facilitates escape from CD19-directed CAR-T cell therapy.

40 unfold to enable tumour eradication by CAR T-cell therapy.

41 ) for treating cancer patients with adoptive cell therapy.

42 otentially have a high impact on neural stem cell therapy.

43 ed T cells with higher efficacy for adoptive cell therapy.

44 g interesting avenues for muscular dystrophy cell therapy.

45 nvironment may influence the success of stem cell therapy.

46 xic T cell-mediated killing, improving CAR T cell therapy.

47 he feasibility and safety of gene editing in cell therapy.

48 e antibodies and chimeric antigen receptor T cell therapy.

49 to exploit their tolerogenic properties for cell therapy.

50 alable ex vivo T-cell expansion for adoptive cell therapy.

51 ngs of checkpoint blockade, such as adoptive cell therapies.

52 , tissue engineering, and spatially targeted cell therapies.

53 valuable models for HIV-1 research and stem cell therapies.

54 g of user-defined responses when designing T-cell therapies.

55 perties and functionalities for personalized cell therapies.

56 studies involving systemically administered cell therapies.

57 r the development of effective vaccine and T-cell therapies.

58 irst metabolic modification to enhance CAR-T cell therapies.

59 d to disease recurrence following many CAR T-cell therapies.

60 ave become the emerging source of autologous cell therapies.

61 mammalian cellular processes and to engineer cell therapies.

62 es for disease modeling, drug screening, and cell therapies.

63 uring adult neurogenesis, and following stem cell therapies.

64 sistent with those reported with other CAR T-cell therapies.

65 ain development and the search for potential cell therapies.

66 of monoclonal antibodies and immune effector cell therapies.

67 accelerate discovery of knockin programs for cell therapies.

68 ated with blinatumomab treatment and other T-cell therapies.

69 reduce the toxicities associated with CAR T cell therapies.

70 is targeted as part of treatment in adoptive cell therapy (ACT) because of its protumor effects and i

71 (T(mem)) are superior mediators of adoptive cell therapy (ACT) compared with effector CD8(+) T cells

72 in a subset of patients following adoptive T cell therapy (ACT) of ex vivo expanded tumor-infiltratin

73 Adoptive T cell therapy (ACT) using ex vivo-expanded autologous tum

74 Adoptive T cell therapy (ACT) with genetically modified T cells has

75 Adoptive cell therapy (ACT) with tumor-specific T cells can media

76 new targets for the development of gene and cell therapies against brain metastases.

77 SCs) provide unprecedented opportunities for cell therapies against intractable diseases and injuries

78 approach to prevent antigen escape in CAR-T cell therapy against MM, and the vertically integrated o

79 cell-mediated anti-tumour immunity and CAR T-cell therapy against solid tumours.

80 where patients' own cells are used for stem cell therapies and immunotherapies.

81 ch will add an additional level of safety to cell therapies and therefore enable the development of a

82 hinder our understanding of so-called 'stem' cell therapies and, although the off-label administratio

83 y observed after chimeric antigen receptor T-cell therapy and are associated with regional EEG abnorm

84 rces of T cells for optimal allogeneic CAR-T cell therapy and describe the different technological ap

85 pocytes in vitro, their potential utility in cell therapy and drug discovery has not been reported.

86 Utilizing flow cytometry, adoptive cell therapy and genetic approaches, we discovered a new

87 e clinical safety of CMV-specific adoptive T-cell therapy and its potential therapeutic benefit for S

88 retinal repair is possible by combining stem cell therapy and optogenetics.

89 T cells might improve the efficacy of CAR T-cell therapy and other emerging cellular immunotherapies

90 vide a background on the field of adoptive T-cell therapy and the development of genetically modified

91 (85%) of 53 patients who received CD19 CAR T-cell therapy and were evaluable for response achieved MR

92 ariety of agents, including small molecules, cell therapies, and antibodies, which may be dosed intra

93 e therapies targeting the brain and the eye, cell therapies, and pharmacological drugs that could mod

94 Engineered nerve guidance conduits, stem cell therapies, and transient electrical stimulation hav

95 protocols of hPSCs for disease modelling and cell therapy, and in high-throughput drug and toxicity s

96 ical studies have demonstrated the safety of cell therapy, and preclinical research has used models o

97 resources for disease modeling, toxicology, cell therapy, and regenerative medicine.

98 urvey also indicates that gene therapy, stem cell therapy, and target discovery through genomic resea

99 we selected either blinatumomab or CD19CAR T-cell therapy, and the rationale behind each decision.

100 ving lineage tracing, the evaluation of stem cell therapy, and transgenesis in ferret models of human

101 zed 3D microenvironment for patient-specific cell therapy applications.

102 method to expand GZMB(+) B cells for future cell therapy applications.

103 9-directed chimeric antigen receptor (CAR) T-cell therapy approved for relapsed/refractory large B-ce

104 Within this class, immune cell therapies are among the most advanced, having alrea

105 Stem cell therapies are limited by poor cell survival and eng

106 NK cell therapies are monitored through measuring periphera

107 CD19-specific CAR-T cell therapies are the gold standard of adoptive cellula

108 tumors to chimeric antigen receptor (CAR) T cell therapy are often minimal.

109 eric antigen receptor-modified T-cell (CAR-T-cell) therapy are limited.

110 th T cell checkpoint blockade and adoptive T cell therapy as cancer immunotherapies.

111 tool for the development of next generation cell therapies, as it allows the user to augment therape

112 ent therapies, oligonucleotides and gene and cell therapies, as well as drug repurposing.

113 roup and the MD Anderson Cancer Center CAR T Cell Therapy-Associated Toxicity (CARTOX) Program have c

114 sented with neurotoxic syndromes after CAR T-cell therapy at the Massachusetts General Hospital.

115 , we create a 'targetable landscape' for CAR cell therapies based on 13,206 proteins and RNAs across

116 linical situation that may be benefited from cell therapies based on regenerative medicine.

117 Cell therapy based on local injection of BM-MSCs or AT-M

118 ered bacteria-effectively taking a bacterial cell therapy-based approach.

119 culture, bleeding control, and molecular and cell therapies because the fibrous networks facilitate b

120 hlighting the feasibility of extending CAR-T cell therapies beyond canonical B-cell malignancies.

121 as immune checkpoint blockade and adoptive T-cell therapy, boost T-cell activity against the tumor, b

122 eliorate the potential risks associated with cell therapies but currently rely on the introduction of

123 CRISPR knockin targeting can improve cell therapies, but more high-throughput methods are nee

124 s determining the utility of anti-CD19 CAR T-cell therapy, but long-term follow-up of patients treate

125 kpoint genes could improve the efficacy of T cell therapy, but the first necessary undertaking is to

126 to better unleash the potential of adoptive cell therapies by enhancing T cell metabolism.

127 otential to extend the therapeutic impact of cell therapies by serving as carriers that provide 3D or

128 highlight recent strategies to improve CAR-T cell therapy by engineering (1) the CAR protein, (2) T c

129 Anti-CD19 chimeric antigen receptor (CAR) T cell therapies can cause severe cytokine-release syndrom

130 Chimeric antigen receptor-T (CAR-T) cell therapies can eliminate relapsed and refractory tum

131 he high response rates after anti-CD19 CAR T-cell therapy can be used to guide the use of therapy in

132 These results demonstrate noninvasive cell therapy characterization can be achieved with QBAM

133 The current study investigates the scope of "cell therapy" clinics across the U.S. that advertise and

134 ents about treatments offered at commercial "cell therapy" clinics.

135 ods for multiple ocular conditions at these "cell therapy" clinics.

136 had in common the use of donor or recipient cell therapy combined with organ transplantation.

137 , human pluripotent stem cell (hPSC)-derived cell therapies continue to have serious safety risks.

138 edge and approaches predicated on the use of cell therapies, cytokines to augment immune responses an

139 This novel method of cell therapy delivery provides an exciting opportunity t

140 An "off-the-shelf" cell therapy derived from induced pluripotent stem cells

141 ignancies, multiple clinical trials of CAR T cell therapy directed to CD19 have led to the approval o

142 Cell therapy efforts for treating HIV+ patients are chal

143 al impact in broadening application of CAR-T cell therapy, especially for solid tumors.

144 Our CAR T-cell therapy exhibited cytotoxicity against both leukemi

145 As the use of CAR T-cell therapy expands to include a wider patient populati

146 t and may provide valuable insights into new cell therapies for autoimmunity.

147 and may improve the overall safety of CAR T-cell therapies for cancer patients.

148 Given their promise in adoptive cell therapies for cancer, a deeper understanding of reg

149 will summarize the current status of immune cell therapies for cancer, infectious disease, and autoi

150 ier to clinical translation of cardiomyocyte cell therapies for heart disease.

151 but also provide potential prospects for new cell therapies for nervous system disorders and injury.

152 However, the development of CAR-T cell therapies for solid tumors is hampered by the lack

153 both insulin delivery and insulin-producing cell therapies for type 1 diabetes management.

154 veillance against, and optimizing adoptive T cell therapies for, gammaHV-associated lymphomas.

155 ell lymphoma showed the feasibility of CAR T-cell therapy for cancer in this excluded group.

156 , adoptive chimeric antigen receptor (CAR) T cell therapy for cancer requires further improvement and

157 enues for improving the efficacy of adoptive cell therapy for cancer.

158 epresent a therapeutic advance in allogeneic cell therapy for cardiac repair.

159 for the development of nanoparticle-enabled cell therapy for infectious diseases.

160 ncourage the clinical use of adoptive T(reg) cell therapy for non-immune diseases, such as neurologic

161 ss is a major barrier to translation of stem cell therapy for pathologies of the brain and spinal cor

162 ta support the safety of CD19-specific CAR T-cell therapy for R/R B-ALL.

163 Chimeric antigen receptor (CAR)-T-cell therapy for solid tumors is limited due to heteroge

164 Cell therapy for the injured spinal cord will rely on co

165 We investigated T-cell therapy for the treatment of metastatic human papil

166 ment, and analyze U.S. businesses marketing "cell therapy" for ocular conditions as of September 16,

167 cs across the U.S. that advertise and offer "cell therapy" for ocular conditions based on information

168 Six non-randomised phase 1/2A cell therapy group (CTG) trials were pooled and analysed

169 Cell therapy has already had an important impact on heal

170 Chimeric antigen receptor T cell therapy has become an important tool in the treatme

171 Although adoptive T-cell therapy has been successfully used in hematopoietic

172 rapidity of commercial utilization of CAR-T-cell therapy has created a largely unexplored gap in pat

173 Recently, cell therapy has emerged as a novel method for treating

174 More recently, cell therapy has gained a growing interest in the heart

175 9-directed chimeric antigen receptor (CAR) T-cell therapy has had a resounding effect on the treatmen

176 Chimeric antigen receptor (CAR)-T cell therapy has had unprecedented impact in the treatme

177 Chimeric antigen receptor (CAR) T-cell therapy has produced remarkable anti-tumor response

178 Chimeric antigen receptor (CAR) T-cell therapy has proven effective in relapsed and refrac

179 Encapsulated cell therapy has shown great potential in the treatment

180 Chimeric antigen receptor (CAR) T cell therapy has shown promise in hematologic malignanci

181 Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy has shown remarkable activity in patients w

182 Chimeric antigen receptor (CAR)-T cell therapy has shown remarkable clinical efficacy agai

183 Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy has shown remarkable clinical efficacy in B

184 Although adoptive T-cell therapy has shown remarkable clinical efficacy in h

185 Chimeric antigen receptor T-cell (CAR T-cell) therapy has been shown to be clinically effective

186 While a variety of cell therapies have been explored, we focus here on the

187 Stem cell therapies have emerged as compelling candidates due

188 Although Treg-based cell therapies have shown immense promise, methods to op

189 ndeed, early-phase clinical trials of T(reg) cell therapy have shown feasibility, tolerability and po

190 e growing emphasis on personalized medicine, cell therapies hold great potential for their ability to

191 eview, we discuss the obstacles facing CAR T cell therapy, how these relate to our current understand

192 ractive cell source for cartilage repair and cell therapy; however, the underlying molecular pathways

193 Cell therapy improved heart function through an acute st

194 the-art clinical data on CD19-directed CAR T cell therapies in B cell hematologic malignancies, advan

195 Increases in the number of cell therapies in the preclinical and clinical phases ha

196 y and/or prevent the widespread use of CAR T cell therapies in these patients as well as in those wit

197 associated with chimeric antigen receptor T-cell therapy in a consecutive series of 100 patients up

198 finally targeting the myocardium directly by cell therapy in an attempt to regenerate new myocardial

199 ally, we envision that the success of T(reg) cell therapy in autoimmunity and transplantation will en

200 to identify a possible window of action for cell therapy in cardiac diseases.

201 esses with chimeric antigen receptor (CAR) T cell therapy in early clinical trials involving patients

202 developed here will be useful for optimising cell therapy in kidney diseases.

203 Here we examine the mechanistic basis for cell therapy in mice after ischaemia-reperfusion injury,

204 ngs may explain the persistent failure of NK cell therapy in patients with solid tumors and highlight

205 9-directed chimeric antigen receptor (CAR) T-cell therapy in pediatric and young adult (AYA) relapsed

206 post-approval evaluation of anti-CD19 CAR T-cell therapy in people with HIV and aggressive B-cell ly

207 the challenges and perspectives of MSC-based cell therapy in SOT.

208 s) are ideal for developing patient-specific cell therapy in temporal lobe epilepsy (TLE).

209 The application of adoptive T cell therapies, including those using chimeric antigen r

210 rapies, other immunomodulators, and adaptive cell therapy, including chimeric antigen T-cell receptor

211 ties to enhance the sophistication of immune cell therapies, increasing potency and safety and broade

212 eg cells the safest cells to use in adoptive cell therapy, increasingly used to treat autoimmune and

213 natal mice exposed to hyperoxia.Conclusions: Cell therapy involving c-KIT(+) EC progenitors can be be

214 hat can be targets for cancer vaccines and T cell therapies is a challenge.

215 Chimeric antigen receptor T (CAR-T) cell therapy is a new pillar in cancer therapeutics; how

216 Therefore, immune cell therapy is a potentially useful therapeutic approac

217 T cell therapy is a promising means to treat chronic HBV i

218 Regulatory cell therapy is achievable and safe in living-donor kidn

219 Genetically engineered T-cell therapy is an emerging treatment of hematologic can

220 esponse to chimeric antigen receptor (CAR) T cell therapy is correlated with CAR T cell persistence,

221 CAR-T cell therapy is effective for hematologic malignancies.

222 d delivery of stem cells in biomaterials for cell therapy is gaining popularity but experimental rese

223 The main adverse effect of CAR T-cell therapy is potentially life-threatening cytokine re

224 The functional benefit of cardiac cell therapy is thus due to an acute inflammatory-based

225 ogressive disease and where autologous CAR-T-cell therapy is unavailable.

226 To address allogeneic cell therapy limitations, this study developed a new all

227 The synergetic effects of the combinatorial cell therapy may have significant impacts on regenerativ

228 the combination of long-term VAD support and cell therapy may offer significant advantages over using

229 anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, may have benefit in patients with relapsed

230 present study aims to design multifunctional cell therapy microcarriers with the capability of sequen

231 safety of chimeric antigen receptor (CAR) T cell therapies, micrometre-sized ICEp were injected intr

232 ts and provides the rationale to apply CAR T-cell therapy more broadly in ALL therapy.

233 ed TCRs against NY-ESO-1 can make adoptive T cell therapy more effective.

234 tumor-specific T cells followed by adoptive cell therapy must yield T cells able to home to tumors a

235 GABAergic potentiators for pro-neurogenic or cell therapies of AD.

236 Chimeric antigen receptor (CAR) T-cell therapy of B-cell malignancies has proved to be eff

237 l to boost MSCs population required for stem cell therapy of bone defects.

238 dication in two mouse models of allogeneic T-cell therapy of hematopoietic and solid cancers.

239 Combined cell therapy of vessel-forming cells and renal tubule-fo

240 te immune responses and may therefore enable cell therapy on a broader scale.

241 estigated the effects of mesenchymal stromal cell therapy on the blood-brain barrier, astrocyte activ

242 of the art of the effects of VAD support and cell therapy on the reverse remodeling of the failing my

243 been reported, the potential benefit of this cell therapy on treatment-resistant depression is unknow

244 es, interventions can be tailored to improve cell therapy or mimic the qualities of reparative cells.

245 from chimeric antigen receptor T cell (CAR-T cell) therapy patients without washing away excess serum

246 Cell therapies present an entirely new paradigm in drug

247 Cell therapy presents the ideal attributes of a promisin

248 an (vCJD) and bovine (BSE) prions in a human cell therapy product candidate.

249 Gene and cell therapy products approved over the past decade in E

250 logy to produce better vaccines and adoptive cell therapy products.

251 ved experimental sepsis, mesenchymal stromal cell therapy protected blood-brain barrier integrity, re

252 Adoptive cell therapy represents a new paradigm in cancer immunot

253 T cell therapies require the removal and culture of T cell

254 CAR T-cell therapy research and development has built on exper

255 We also identify future avenues for NK cell therapy research.

256 s the short-term strategies to improve CAR T-cell therapy responses, particularly for solid tumours,

257 bitors and CAR (chimeric antigen receptor) T-cell therapy serve as excellent examples of the possibil

258 guide future NK cell priming strategies in a cell therapy setting.

259 nes with checkpoint inhibitors or adoptive T cell therapy should be evaluated for possible clinical b

260 off-label administration of intra-articular cell therapies (such as platelet-rich plasma and bone ma

261 e the new backbone of anti-MM therapy, and T-cell therapies targeting BCMA are emerging as the most p

262 Autologous chimeric antigen receptor (CAR) T cell therapies targeting CD19 have high efficacy in larg

263 ient immune-cell researchers to test novel T-cell therapies targeting soluble ligands in <2 weeks.

264 The potency of adoptive T cell therapies targeting the cell surface antigen CD19 h

265 (MM) that is resistant to conventional CAR-T cell therapy targeting B-cell maturation antigen (BCMA).

266 a rationale for the future use of adoptive T cell therapy targeting neoantigens in bladder cancer.

267 Chimeric antigen receptor (CAR) T-cell therapy targeting solid tumors has stagnated as a r

268 g iPSCs' self-renewal ability to manufacture cell therapies that don't require customization for each

269 bb2121, a chimeric antigen receptor (CAR) T-cell therapy that targets B-cell maturation antigen (BCM

270 The anti-CD19 chimeric antigen receptor T-cell therapy tisagenlecleucel (CTL019) has an 81% respon

271 The chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel targets and eliminates CD1

272 Two CAR T-cell therapies, tisagenlecleucel and axicabtagene cilole

273 Paradoxically, cell therapies to offset cardiomyocyte loss after ischem

274 ata demonstrate the potential of neural stem cell therapies to restore normal myelination and protect

275 ns in the view of the growing use of myeloid cell therapies to treat brain disease in humans.

276 ngs reveal a fundamental limitation to CAR-T cell therapy to eradicate HIV.

277 ble candidate agent for development of novel cell therapy to improve allograft survival after transpl

278 ration, we exploited the methodology used in cell therapy to numerically expand NK cells in the prese

279 rapid translation of this novel SARS-CoV-2 T-cell therapy to the clinic), membrane, spike, and nucleo

280 ion presents a minimally invasive and robust cell-therapy to restore hormonal balance in ovarian insu

281 Forty companies with 76 clinics use "cell therapy" to treat ocular conditions.

282 To actuate the therapeutic potential of cell therapy toward worldwide clinical use, cell deliver

283 Furthermore, in an adoptive cell therapy treated melanoma cohort, NMD-escape mutatio

284 The rationale for these cell therapy trials is derived from animal studies that

285 Chimeric antigen receptor T-cell therapies using defined product compositions requir

286 iabetic mouse cutaneous wound model in vivo, cell therapies using diabetic cells with GLO1 overexpres

287 In this review, we discuss the evolution of cell therapies with a focus on stem cell advantages, as

288 of neurologist preparedness to discuss stem cell therapies with patients and an alarming list of unr

289 CD19 CAR T-cell therapy with concurrent ibrutinib was well tolerate

290 duce cell sheet technology as a breakthrough cell therapy with demonstrated therapeutic success acros

291 Adoptive cell therapy with genetically modified T cells has gener

292 aplasia caused by TBI could be alleviated by cell therapy with human bone marrow mesenchymal stromal

293 g a standardized off-the-shelf engineered NK cell therapy with improved ADCC properties to treat mali

294 ularly for solid tumours, by combining CAR T-cell therapy with radiotherapy through the use of carefu

295 resent a rapidly emerging form of adoptive T-cell therapy with the potential to overcome safety and a

296 poietic stem cell-engineered iNKT (HSC-iNKT) cell therapy with the potential to provide therapeutic l

297 preclude durable remissions following CAR T cell therapy, with a primary focus on the resistance mec

298 e patients were 38% and 50% after CD19 CAR T-cell therapy, with and without concurrent ibrutinib, res

299 lied to monitor both tumour burden and CAR T cell therapy within a systemically induced mouse tumour

300 Chimeric antigen receptor (CAR) T cell therapy works by mechanisms distinct from those of